

# Financial Tear Sheet

## Corporate Profile

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other *in vitro* diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.



OraSure Technologies is the leading supplier of oral-fluid collection devices and *in vitro* diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, *in vitro* diagnostic tests, and other medical devices.



## Usage Terms and Disclaimers

Your usage of this Web site and the information and materials contained therein are subject to the disclaimers and other provisions set forth in the Web site, under Usage Terms, Update Notice and Privacy Policy. Links to these provisions are located at the bottom of each page of this Web site.

## Stock Performance

### OSUR (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$14.77</b>
Change (%)	▼ 0.04 (0.27%)
Volume	400,882
52 Week Low	\$12.86
Market Cap	\$903,532,935
Rolling EPS	0.37
PE Ratio	40.4225
Shares Outstanding	61,173,523

Data as of 10/19/18 4:00 p.m. ET



**Recent Headlines & Events**

10/08/18 - 6:00 a.m.

[OraSure Technologies Earnings Conference Call Invitation](#)

09/26/18 - 6:00 a.m.

[OraSure Technologies to Present at the Cantor Global Healthcare Conference](#)

09/06/18 - 6:00 a.m.

[OraSure Technologies to Present at the CL King 16th Annual Best Ideas Conference](#)

**Analyst Estimates / Ratings**

Mean Recommendation: 2.3



Sell

Strong Buy

**SEC Filings**

Filing Date	Form
10/04/18	<a href="#">8-K/A</a>
08/29/18	<a href="#">4</a>
08/23/18	<a href="#">8-K</a>
08/17/18	<a href="#">8-K</a>

Date	Title
11/07/18 5:00 p.m. ET	<a href="#">Q3 2018 OraSure Technologies, Inc. Earnings Conference Call</a>

Unable to fulfill request.

**Executive Officers**

- [Stephen S. Tang, Ph.D.](#) President and CEO, OraSure Technologies, Inc.
- [Roberto Cuca](#) Senior Advisor and Chief Financial Officer
- [Tony Zezzo](#) Executive Vice President, Business Unit Leader, Infectious Disease
- [Jack E. Jerrett](#) Senior Vice President, General Counsel and Secretary
- [Mark L. Kuna](#) Senior Vice President, Finance, Controller and Assistant Secretary
- [Nancy J. McLane](#) Senior Vice President, Operations
- [David Rappaport, CFA](#) Senior Vice President, Business Development
- [Michael Reed, Ph.D](#) Senior Vice President, Research and Development and Chief Science Officer
- [Brian Smith](#) Senior Vice President, Business Unit leader, Molecular Solutions
- [Kathleen Weber](#) Senior Vice President and General Manager, Consumer Products

Data provided by Nasdaq. Minimum 15 minutes delayed.

Minimum 20 minutes delayed